Insider buy at Kala Pharmaceuticals (KALA) Extends the Trend of purchases over Last Quarter

Friday, February 02, 2018 10:15 PM ET

Insider buy at Kala Pharmaceuticals (KALA) Extends the Trend of purchases over Last Quarter

Notable insider buying activity was disclosed in Kala Pharmaceuticals shares in a form 4 document filed with the SEC today, showing — OrbiMed Advisors Llc, 10% Owner — purchased 362,240 shares in the company having a net market value of approximately $5,433,372. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the purchase of 570,529 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 932,769 shares and have averaged 466,385 shares per transaction over this time period.

Kala Pharmaceuticals insider trading represents a higher number of buy/sell trades than for the 280 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 328 buy/sell trades during this period for an average of 1.2 transactions per company. The number of shares per buy/sell trade for Kala Pharmaceuticals insiders was also higher. Within the peer group there were 33,200,273 shares purchased and 43,369,855 shares sold with company insiders selling 31,005 shares on average.

The data sourced in evaluating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.